Nicia Isabella Profili

Dr. Nicia Isabella Profili


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Roberto CastelliRoberto Castelli
Roberto Castelli
AGAntonio Gidaro
Antonio Gidaro
GCGavino Casu
Gavino Casu
PMPIERLUIGI MERELLA
PIERLUIGI MERELLA
NPNicia Isabella Profili
Nicia Isabella Profili
Alessandro DelitalaAlessandro Delitala
Alessandro Delitala
Aging of the vascular system is associated with deep changes of the structural proprieties of the arterial wall. Arterial hypertension, diabetes mellitus, and chronic kidney disease are the major determinants for the loss of elasticity and reduced compliance of vascular wall. Arterial stiffness is a key parameter for assessing the elasticity of the arterial wall and can be easily evaluated with non-invasive methods, such as pulse wave velocity. Early assessment of vessel stiffness is critical because its alteration can precede clinical manifestation of cardiovascular disease. Although there is no specific pharmacological target for arterial stiffness, the treatment of its risk factors helps to improve the elasticity of the arterial wall.

25 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NPNicia Isabella Profili
Nicia Isabella Profili
Roberto CastelliRoberto Castelli
Roberto Castelli
AGAntonio Gidaro
Antonio Gidaro
RMRoberto Manetti
Roberto Manetti
MMMargherita Maioli
Margherita Maioli
Alessandro DelitalaAlessandro Delitala
Alessandro Delitala
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women during the fertile period. Women with PCOS have an increased risk of developing major cardiovascular risk factors during the fertile period: obesity, impaired glucose tolerance, diabetes mellitus, dyslipidemia, and metabolic syndrome. The possible effect of PCOS on cardiovascular disease (CVD) has been reported in different studies, but the results are not clear for several reasons. Indeed, most of the studies analyzed a cohort of fertile women who, given their relatively young age, have a low frequency of cardiovascular diseases. In addition, longitudinal studies have a short follow-up period, insufficient to draw firm conclusions on this topic. Finally, pharmacological treatment is limited by the lack of specific drugs available to specifically treat PCOS. In this review, we report on studies that analyzed the possible effect of PCOS on the most common CVD (hypertension, arterial stiffness, atherosclerosis, and cardiovascular event) and available drugs used to reduce CVD in PCOS women.

7 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NPNicia Isabella Profili
Nicia Isabella Profili
Roberto CastelliRoberto Castelli
Roberto Castelli
AGAntonio Gidaro
Antonio Gidaro
AMAlessandro Merella
Alessandro Merella
RMRoberto Manetti
Roberto Manetti
Alessandro DelitalaAlessandro Delitala
Alessandro Delitala
Checkpoint inhibitors are monoclonal antibodies that elicit an anti-tumor response by stimulating immune system. Their use has improved the treatment of different types of cancer such as melanoma, breast carcinoma, lung, stomach, colon, liver, renal cell carcinoma, and Hodgkin’s lymphoma, but several adverse events have been reported. Although the etiology of these effects is not completely understood, an uncontrolled activation of the immune system has been postulated. Indeed, some studies showed a cross reactivity of T cells, which acted against tumor antigens as well as antigens in the tissues of patients who developed immune-related adverse events. Despite the known possibility of developing immune-related adverse events, early diagnosis, monitoring during therapy, and treatment are fundamental for the best supportive care and administration of immune checkpoint inhibitors. The aim of this review is to guide the clinician in early diagnosis, management, and treatment of the endocrinological adverse effects in the major endocrine glands (thyroid, pituitary, adrenal, endocrine pancreas, and parathyroid).

Verified
Journal Article
Open access
PDF file
NPNicia Isabella Profili
Nicia Isabella Profili
EFEdoardo Fiorillo
Edoardo Fiorillo
VOValeria Orrù
Valeria Orrù
FCFrancesco Cucca
Francesco Cucca
Alessandro DelitalaAlessandro Delitala
Alessandro Delitala
Growth differentiation factor 15 (GDF15) is a stress-response cytokine, which exerts different actions in physiological and pathological conditions. Thyroid disorders are common in the general population and their role on GDF15 levels has not been sufficiently addressed. Serum levels of GDF-15 and thyroid function were assessed in a large sample from the SardiNIA cohort (n = 4413). We further collected antibodies against thyroperoxidase and anti-thyroglobulin in all participants. Thyroid function correlated with GDF15. Specifically, after adjusting for covariates, thyrotropin had a positive association with GDF15, while free thyroxine was negatively correlated. We also found that subjects with circulating antibodies against thyroperoxidase had lower GDF15 levels. The reduced level of the thyroid hormone can cause a decreased metabolic activity and higher cell stress response, which, in turn, increases the production of GDF-15 as a defense mechanism. The association between antibodies against thyroperoxidase and GDF15 deserves additional study to elucidate the pathophysiologic relationship.

9 April 2024 in Life
Verified
Journal Article
Open access
PDF file
Roberto CastelliRoberto Castelli
Roberto Castelli
ABAlessandra Berzuini
Alessandra Berzuini
RMRoberto Manetti
Roberto Manetti
Alessandro DelitalaAlessandro Delitala
Alessandro Delitala
DCDante Castro
Dante Castro
AGAntonio Gidaro
Antonio Gidaro
Background: Myeloproliferative neoplasms (MPNs) are often associated with splanchnic vein thrombosis (SVT). Not all the factors involved in the thrombotic tendency are currently known. Objectives: This study aims to evaluate a possible association between ADAMTS13, von Willebrand factor (VWF), platelet microvesicles (MV), and factor VIII activity (FVIII:C) with thrombotic events in MPN patients. Materials and methods: In total, 36 consecutive MPN patients with SVT were enrolled. The MPNs were diagnosed based on clinical characteristics and one or more gene mutations among JAK-2, CALR, and MPL. As controls, 50 randomly selected patients with MPN without thrombosis, 50 patients with deep vein thrombosis without MPNs, and 50 healthy blood donors were evaluated. Complete blood count, ADAMTS13, VWF, MV, and FVIII:C in plasma were measured in all the subjects. Results: The JAK-2 mutation was found in 94% of the patients with SVT, but none were triple-negative for genetic mutations (JAK2 V617F, CALR, MPL, and exon 12). Compared to the normal subjects, in all the MPN patients (with or without SVT), the levels of ADAMTS13 were found to be significantly lower (p < 0.001) and the MV concentrations were significantly higher (p < 0.001). Among the MPN patients, the VWF and FVIII:C levels were significantly higher in the patients with SVT than those without thrombosis (p = 0.007 and p = 0.04, respectively). Splenomegaly was present in 78% of MPN patients with SVT and in 30% of those without SVT (p < 0.001). The ADAMTS13/VWF ratio was reduced in all the patients, but not in the healthy blood donors (p < 0.001). Conclusions: The significant increase in circulating MV, VWF, and FVIII:C in the MPN patients and in the patients with thrombosis supports the role of endothelium damage in promoting thrombotic events. In particular, a significant increase in VWF and FVIII:C levels was found in the MPN patients with SVT.

15 March 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
NPNicia Isabella Profili
Nicia Isabella Profili
Roberto CastelliRoberto Castelli
Roberto Castelli
RMRoberto Manetti
Roberto Manetti
Marta Chiara SircanaMarta Chiara Sircana
Marta Chiara Sircana
MPMichela Pagni
Michela Pagni
Alessandro DelitalaAlessandro Delitala
Alessandro Delitala
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are a specific class of drugs originally developed for treating type 2 diabetes mellitus. Subsequently, studies demonstrated that their action was not limited to glycemic control but could also have positive effects on other specific outcomes, particularly at the cardiovascular level. Indeed, due to their diuretic effect, SGLT2i improve the clinical control of chronic heart failure and reduce the risk of rehospitalization. In addition, other studies reported a protective effect on major cardiovascular events and mortality. More recently, it has been suggested that the prescription of SGLT2i after an acute myocardial infarction may have positive effects due to their possible effect on inflammation, arrhythmias, and ventricular remodeling. Here, we reviewed studies focused on SGLT2i after an acute myocardial infarction in patients treated with percutaneous coronary intervention.